Alzheimer’s research has spent decades chasing plaques and tangles. A Massachusetts company is now preparing to test a different idea in patients: that helping the brain clear its own waste fluid more effectively could slow the disease. The US Food and Drug Administration has granted CereVasc an investigational device exemption for its eShunt System in Alzheimer’s disease, as reported in today’s medical device news, clearing the way for a clinical trial of the implant in a condition that affects an estimated 7.4 million Americans over 65.
How the eShunt System Works
The device is implanted through a minimally invasive endovascular procedure and creates a controlled path for cerebrospinal fluid to drain into the venous system. Cerebrospinal fluid continuously bathes the brain and spinal cord, carrying away metabolic waste, and its circulation is known to falter with age. By increasing that cycling, CereVasc hopes to improve the clearance of neurotoxic substances associated with Alzheimer’s pathology. The company built its experience in a separate trial, known as STRIDE, using the same platform to treat normal pressure hydrocephalus, a condition of fluid build-up that can mimic dementia.
A Field Looking Beyond One Theory
The clearance reflects a broader shift in Alzheimer’s research. Antibody drugs that remove amyloid have delivered modest benefits at considerable cost and risk, pushing investigators towards complementary mechanisms — inflammation, vascular health, sleep and fluid dynamics among them. Device-based approaches carry their own hazards, including surgical risk in frail patients, which is why regulators require staged trials. Still, the willingness to test a plumbing-based hypothesis in a major trial signals how far the field has moved, echoing the pragmatic trial culture seen in work such as the major trial of glucose monitors in type 2 diabetes.
What Happens Next
An investigational device exemption is permission to study, not proof of benefit. CereVasc must now recruit patients, demonstrate safety and then show whether enhanced fluid clearance changes cognition or disease markers. With the Alzheimer’s population projected to reach 13.8 million Americans by 2060, even a partial success would matter — but the history of the field counsels patience.
Sceptics counsel that Alzheimer’s has humbled many elegant theories, and that fluid dynamics may interact with amyloid and tau in ways a single-device trial cannot fully untangle. CereVasc’s staged approach — safety first, then signals of biological effect — reflects that humility. The hydrocephalus programme gives the company human data on the platform itself, an advantage most Alzheimer’s device startups lack when they approach regulators.
For patients and families, nothing changes today: there is no new treatment to request and no change to existing care. What the FDA’s decision buys is a fair test of an idea that, until now, lived mostly in theory.


